CUPERTINO, California :Apple said on Monday it will open up the underlying technology it uses for Apple Intelligence and announced an overhaul of its operating systems.The tone and content of the ...

Zodiacs & Astrology News: In a quirky fusion of astrology and sports, the stars align with the characters of 'Haikyu!!', matching zodiac signs to volleyball players. From Aries ...

Takeda has received approval from the European Commission (EC) for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The drug has been approved in combination with the ...

Takeda global oncology business unit president Teresa Bitetti stated: “Today’s approval represents a significant advancement for patients with Hodgkin lymphoma in the EU. “This approval reinforces the ...

US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating ...

Takeda Investor Conference Call and Webcast Details. Takeda will host an investor call regarding this update on Sunday, June 1, 6-6:45 pm CDT/ 7-7:45 pm EDT / Monday, June 2, 08:00-08:45 (JST). The ...

Takeda Investor Conference Call and Webcast Details. Takeda will host an investor call regarding this update on Sunday, June 1, 6-6:45 pm CDT/ 7-7:45 pm EDT / Monday, June 2, ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad. The SERD spectacle, the VERIFY study, and the dream of a better multi-cancer liquid biopsy test.

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...